Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | BHMT | Q93088 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439764 | 1.00 | ENPEP (0.43) | ENPEPLTA4HBHMTALDH1A1GABRP | |
| SCHEMBL337707 | 0.89 | CYP1A2 (0.52) | ENPEPLTA4HGABRPGABRDGABRA1 | |
| SCHEMBL561334 | 0.89 | CYP1A2 (0.52) | ENPEPLTA4HGABRPGABRDGABRA1 | |
| SCHEMBL6740146 | 0.89 | CYP1A2 (0.52) | ENPEPLTA4HGABRPGABRDGABRA1 | |
| SCHEMBL28096244 | 0.87 | CYP1A2 (0.50) | ENPEPLTA4HGABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL3580142 | 0.87 | CYP1A2 (0.50) | ENPEPLTA4HGABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL2124734 | 0.87 | CYP1A2 (0.50) | ENPEPLTA4HGABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL2124740 | 0.87 | CYP1A2 (0.50) | ENPEPLTA4HGABRPGABRDGABRA1 | |
| SCHEMBL23416460 | 0.86 | LTA4H (0.39) | LTA4HCYP1A2SLC1A1MEN1KMT2A | |
| SCHEMBL3176136 | 0.86 | LTA4H (0.39) | LTA4HCYP1A2SLC1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-26 | — | — | US | disclosed |
| CN-121574171-A | Difunctional protein degradation agent of direct targeting proteasome, preparation method and application thereof | 浙大城市学院 | 2026-02-27 | — | — | CN | disclosed |
| CN-120040321-A | Neuraminidase inhibitor based on hydrophobic tag technology and preparation method, derivative, pharmaceutical composition and application thereof | 南方科技大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-116178293-B | Myelin specific magnetic resonance contrast agent, preparation method and application thereof | 滨州医学院附属医院 | 2025-05-09 | — | — | CN | disclosed |
| CN-114716387-B | High affinity agents for prostate specific membrane antigen targeting for intracavity radiation therapy of prostate cancer | 约翰霍普金斯大学 | 2025-04-01 | — | — | CN | disclosed |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | TRIPARTITE THERAPEUTICS INC. (TW) | 2025-01-30 | — | — | US | disclosed |
| CN-114751874-B | 1-Benzyl-4-ethylpiperazine derivatives as TRPV4-KCa2.3 coupling promoters and uses thereof | 江南大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-119161340-A | PROTAC molecule derived based on AZD5305, and preparation method and application thereof | 中国药科大学 | 2024-12-20 | — | — | CN | disclosed |
| CN-119080685-A | Arginine methyltransferase 6 inhibitor, preparation method, pharmaceutical composition and application thereof | 四川大学 | 2024-12-06 | — | — | CN | disclosed |
| CN-116375713-B | DCLK1 protein degradation targeting chimeric and application thereof | 中国人民解放军海军军医大学 | 2024-11-19 | — | — | CN | disclosed |
| EP-0990047-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | Rapigene, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| US-6027890-A | DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY | RAPIGENE, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | disclosed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| WO-1995023811-A1 | NOVEL CARBOCYCLIC COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION BY INTERACTION WITH THE GPIIB/IIIA RECEPTOR COMPLEX | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| EP-0541663-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002542-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1992-02-20 | — | — | WO | disclosed |
| EP-0271041-A2 | Atrial peptide derivatives | ABBOTT LABORATORIES (US) | 1988-06-15 | — | — | EP | disclosed |
| US-RE30731-E | Enkephalin analogues | Hudson, Derek (GB) | 1981-09-01 | — | — | US | disclosed |
| US-4198398-A | Enkephalin analogues | HUDSON DEREK (GB) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | ENPEP 2676/4885LTA4H 3140/4885BHMT 3097/4885 |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | CD274, SELPLG, PDCD1LG2 | ENPEP 329/4885LTA4H 1399/4885BHMT 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.